Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST

Author(s):
Demetri, G.D.; Jeffers, M.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Leahy, M.; Mehren, M. von; Joensuu, H.; Badalamenti, G.; Blackstein, M.; Cesne, A. le; Schoffski, P.; Maki, R.G.; Bauer, S.; Nguyen, B.B.; Xu, J.M.; Nishida, T.; Chung, J.; Lathia, C.D.; Kappeler, C.; Kuss, I.; Laurent, D.; Casali, P.G.
Published
2013
Publication type
Article / Letter to editor
Date issued
2013-04-15
Language
English
Is part of
Cancer Research (2013), No. 8
hdl
1887/104680
doi
10.1158/1538-7445.AM2013-LB-295